Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs)

CONCLUSION: Median OS with both HMAs remained significantly shorter than in the AZA-001 clinical trial, highlighting how patient outcomes vary between clinical and real-world settings. Further research is required to understand why these disparities exist.PMID:37996264 | DOI:10.1016/j.clml.2023.10.010

Source: Clinical Lymphoma and Myeloma - November 23, 2023 Category: Cancer & Oncology Authors: Amer M Zeidan Elizabeth S Mearns Carmen D Ng Anuj Shah Neil Lamarre Archibong Yellow-Duke Neda Alrawashdh Baiyu Yang Wei-Han Cheng Cat N Bui Anders Svensson Source Type: research